# Nab-PCE vs PC for MM After Failure of Anti-PD-1

> **NCT03917069** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 145 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Chemotherapeutic Combinations
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT03917069
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-23
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2019-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03917069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03917069, "Nab-PCE vs PC for MM After Failure of Anti-PD-1". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03917069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*